We are live on ! Find out more
ADIL

Adial Pharmaceuticals
ADIL

14 hedge funds and large institutions have $326K invested in Adial Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

40% more capital invested

Capital invested by funds: $233K → $326K (+$92.2K)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

8% more funds holding

Funds holding: 13 → 14 (+1)

0.16% less ownership

Funds ownership: 0.42% → 0.27% (-0.16%)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$118K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.1K
3
Citadel Advisors
Citadel Advisors
Florida
+$37.4K
4
BlackRock
BlackRock
New York
+$30.4K
5
1IA
1620 Investment Advisors
Massachusetts
+$5.45K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$27K
2
Renaissance Technologies
Renaissance Technologies
New York
-$25.3K
3
HF
HRT Financial
New York
-$9.91K
4
Osaic Holdings
Osaic Holdings
Arizona
-$3.33K
5
HT
Headlands Technologies
Illinois
-$85
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$96.1K +$118K +3,115 +1,360%
MCM
2
Manchester Capital Management
Vermont
$55.3K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$39.5K -$25.3K -670 -33%
HF
4
HRT Financial
New York
$33K -$9.91K -262 -18%
BlackRock
5
BlackRock
New York
$31.9K +$30.4K +805 +263%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$29.8K +$39.1K +1,035 New
Citadel Advisors
7
Citadel Advisors
Florida
$28.5K +$37.4K +990 New
TRCT
8
Tower Research Capital (TRC)
New York
$6.48K +$1.51K +40 +22%
1IA
9
1620 Investment Advisors
Massachusetts
$4.14K +$5.45K +144 New
Bank of America
10
Bank of America
North Carolina
$792 +$1.06K +28 New
Morgan Stanley
11
Morgan Stanley
New York
$45 +$38 +1 +100%
AWM
12
Abound Wealth Management
Tennessee
$32 – – –
Qube Research & Technologies (QRT)
13
Qube Research & Technologies (QRT)
United Kingdom
$10 – – –
VF
14
Virtu Financial
New York
– -$27K -819 Closed
Osaic Holdings
15
Osaic Holdings
Arizona
– -$3.33K -100 Closed
HT
16
Headlands Technologies
Illinois
– -$85 -3 Closed
Wells Fargo
17
Wells Fargo
California
– -$15 – –

ADIL Hedge Fund Activity: Q2 2024 in Review

14 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2024, worth a combined $326K — up 40% from $233K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ADIL positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.

The largest buyer was UBS Group, adding an estimated $118K. The largest seller was Virtu Financial, exiting entirely with an estimated $27K sold.

  • 14 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2024, up from 13 in Q1 2024.
  • Funds reported $326K of Adial Pharmaceuticals stock for Q2 2024, up 40% quarter-over-quarter.
  • 4 funds opened new Adial Pharmaceuticals positions in Q2 2024 and 3 closed out, a net change of +1 holder.
  • The largest Adial Pharmaceuticals buyer in Q2 2024 was UBS Group, an estimated $118K added.
  • The largest Adial Pharmaceuticals seller in Q2 2024 was Virtu Financial, an estimated $27K sold.

Based on aggregated 13F filings for Q2 2024.